Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 3/20 | 0.34 |
| ▸ | TYMP | P19971 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358015 | 0.93 | HSP90AA1 (0.40) | LMNASMN1; SMN2TYMSTYMPHSP90AA1 | |
| SCHEMBL27206891 | 0.93 | HSP90AA1 (0.40) | LMNASMN1; SMN2TYMSTYMPHSP90AA1 | |
| SCHEMBL13930549 | 0.92 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL2031822 | 0.92 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL28600193 | 0.92 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL22984007 | 0.92 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL9550769 | 0.92 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL24263898 | 0.92 | TYMS (0.35) | TYMSTYMPHSP90AA1RNASE1 | |
| SCHEMBL13901245 | 0.92 | RNASE1 (0.40) | TYMSTYMPRNASE1 | |
| SCHEMBL14771517 | 0.92 | RNASE1 (0.40) | TYMSTYMPRNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| WO-2020081744-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | TOLLNINE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TYMP, DUT, PAICS | LMNA 3368/4885ALOX12 2326/4885ADRA1A 4100/4885 |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | LMNA 3368/4885ALOX12 2326/4885ADRA1A 4100/4885 |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | LMNA 1139/4885ALOX12 1718/4885ADRA1A 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.